Status:
UNKNOWN
Study of Aspirin and Exemestane as Adjuvant Treatment in Breast Cancer
Lead Sponsor:
Chinese Academy of Medical Sciences
Conditions:
Breast Neoplasms
Eligibility:
FEMALE
50-80 years
Phase:
PHASE2
Brief Summary
This is a phase II study to assess efficacy/safety of Exemestane with or without Aspirin as the adjuvant treatment in postmenopausal breast cancer patients.
Eligibility Criteria
Inclusion
- Breast cancer after surgery postmenopausal
Exclusion
- contraindication of aspirin
Key Trial Info
Start Date :
July 1 2011
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
July 1 2014
Estimated Enrollment :
160 Patients enrolled
Trial Details
Trial ID
NCT01431053
Start Date
July 1 2011
End Date
July 1 2014
Last Update
March 13 2013
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Beijing, China, 100021